SUPERA 1R
Alternative Names: SUPERA-1R; Supera-CBDLatest Information Update: 28 Jul 2026
At a glance
- Originator MyMD Pharmaceuticals
- Developer TNF Pharmaceuticals
- Class Analgesics; Anti-inflammatories; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Neuroprotectants
- Mechanism of Action Cannabinoid receptor CB2 antagonists; Monoamine oxidase A inhibitors; Monoamine oxidase B inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders; Epilepsy; Inflammatory pain; Seizures; Substance-related disorders
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
- 28 Jul 2026 No recent reports of development identified for preclinical development in Epilepsy in USA
- 28 Jul 2026 No recent reports of development identified for preclinical development in Inflammatory-pain in USA